“翻倍基”扎堆医药赛道

Core Viewpoint - The performance of certain equity funds has been outstanding in the context of a rising market, particularly in the pharmaceutical sector, with a significant number of funds achieving over 100% returns year-to-date and over the past year [1][3][4]. Fund Performance - As of July 29, 23 funds have achieved a year-to-date return of over 100%, with 70% of these being related to the pharmaceutical sector [3][4]. - The leading fund, Huatai-PineBridge Hong Kong Advantage Selected Mixed Fund (QDII) C, has a year-to-date return of 139.12%, followed closely by other funds with returns of 138.9% and 129.35% [3][4]. - Over the past year, a total of 134 funds have doubled their returns, with the top-performing fund, CITIC Securities North Exchange Two-Year Open Mixed A, achieving a remarkable 207.48% return [4][5]. Sector Focus - The majority of the "doubling funds" are focused on innovative drugs and related products, with over 60 funds containing terms like "pharmaceutical," "innovative drugs," and "biotechnology" in their names [4][5]. - The top-performing funds in the innovative drug sector include those managed by well-known fund managers, with returns nearing 100% for some [5][6]. Market Outlook - Industry experts remain optimistic about the innovative drug sector, citing strong performance in the first half of the year and potential for continued growth in the second half [6][7]. - There is an expectation of structural opportunities in the consumer healthcare sector, particularly in areas like medical aesthetics and home medical devices, driven by increasing health awareness among consumers [7][8]. - The outlook for innovative drugs is bolstered by government support measures and anticipated developments in overseas licensing and domestic sales [8].